Dataset Information

Impact of the age expansion of breast screening on screening uptake and screening outcomes among older women in BreastScreen western.

ABSTRACT:

Objectives

To assess the impact of age expansion of screening (EOS) of the target age group from 50 to 69 to 50-74 in Australia, which began mid-2013, by examining screening uptake and outcomes of older women, and by identifying factors associated with continuing screening after reaching the age of 75 years.

Methods

Retrospective study using data from women aged 65+ who attended BreastScreen Western Australia between 2010 and 2017 for free mammograms. Screening uptake and screening outcomes were calculated for the periods before (2010-2012) and after (2015-2017) the age EOS to women aged 70-74. Logistic regression was used to identify variables associated with continuing screening after reaching age 75 years, while controlling for possible confounding variables.

Results

Age EOS increased screening uptake amongst women aged 70-74 b y 36% and amongst women ?75 years by 3% while screening uptake in women aged 65-69 decreased by 3%. Rate of invasive screened-detected cancers significantly decreased among women aged 70-74 from 11.4/1000 screens before to 8.1/1000 screens after age EOS. Likelihood of continuing screening into age ?75 years was higher in women who had a personal history or a family history of breast cancer, or used hormone replacement therapy within six months of screening. Women who were born outside Australia were less likely to continue screening after reaching age 75 years.

Conclusions

Our study found that age EOS to women aged 70-74 was effective in increasing screening uptake in this age-group but was accompanied by a moderate increase in screening uptake amongst women ?75 years via self-referral for whom potential benefit of screening may be limited.

SUBMITTER: El-Zaemey S

PROVIDER: S-EPMC7933533 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Impact of the age expansion of breast screening on screening uptake and screening outcomes among older women in BreastScreen western.

El-Zaemey Sonia S Liz Wylie W Hosseinzadeh Negar N Lund Helen H Mathieu Erin E Houssami Nehmat N

Breast (Edinburgh, Scotland) 20210211

<h4>Objectives</h4>To assess the impact of age expansion of screening (EOS) of the target age group from 50 to 69 to 50-74 in Australia, which began mid-2013, by examining screening uptake and outcomes of older women, and by identifying factors associated with continuing screening after reaching the age of 75 years.<h4>Methods</h4>Retrospective study using data from women aged 65+ who attended BreastScreen Western Australia between 2010 and 2017 for free mammograms. Screening uptake and screenin ...[more]

PMID: 33647788

Similar Datasets

Project description:Background:Biennial screening is generally recommended for average-risk women aged 50 to 74 years, but tailored screening may provide greater benefits. Objective:To estimate outcomes for various screening intervals after age 50 years based on breast density and risk for breast cancer. Design:Collaborative simulation modeling using national incidence, breast density, and screening performance data. Setting:United States. Patients:Women aged 50 years or older with various combinations of breast density and relative risk (RR) of 1.0, 1.3, 2.0, or 4.0. Intervention:Annual, biennial, or triennial digital mammography screening from ages 50 to 74 years (vs. no screening) and ages 65 to 74 years (vs. biennial digital mammography from ages 50 to 64 years). Measurements:Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mammograms, benign biopsy results, overdiagnosis, cost-effectiveness, and ratio of false-positive results to breast cancer deaths averted. Results:Screening benefits and overdiagnosis increase with breast density and RR. False-positive mammograms and benign results on biopsy decrease with increasing risk. Among women with fatty breasts or scattered fibroglandular density and an RR of 1.0 or 1.3, breast cancer deaths averted were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of 3.4 to 5.1 vs. 4.1 to 6.5 deaths averted; 65 to 74 years, median of 1.5 to 2.1 vs. 1.8 to 2.6 deaths averted). Breast cancer deaths averted increased with annual versus biennial screening for women aged 50 to 74 years at all levels of breast density and an RR of 4.0, and those aged 65 to 74 years with heterogeneously or extremely dense breasts and an RR of 4.0. However, harms were almost 2-fold higher. Triennial screening for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $100 000 per QALY gained. Limitation:Models did not consider women younger than 50 years, those with an RR less than 1, or other imaging methods. Conclusion:Average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density receiving annual screening will maintain a similar or better balance of benefits and harms than average-risk women receiving biennial screening. Primary Funding Source:National Cancer Institute.

Dataset Information

Impact of the age expansion of breast screening on screening uptake and screening outcomes among older women in BreastScreen western.

Objectives

Methods

Results

Conclusions

Publications

Impact of the age expansion of breast screening on screening uptake and screening outcomes among older women in BreastScreen western.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure